Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03217565 · ClinicalTrials.gov registry record · Phase 1
A Pharmacokinetic Study of Tedizolid Phosphate in Pediatric Participants With Gram-Positive Infections (MK-1986-014)
A Phase 1 study, sponsored by Merck Sharp & Dohme.
- Completed
- Registry status
- Phase 1
- Development phase
- 47
- Enrollment target
NCT03217565 is a Phase 1 study that has completed, run by Merck Sharp & Dohme. The registered enrollment target is 47 participants.
The verdict
NCT03217565, a Phase 1 study, has completed, sponsored by Merck Sharp & Dohme.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 47 participants
- Enrollment target
Study Summary
The primary objectives of this study are to describe the single-dose, and multiple dose pharmacokinetics (PK) of intravenous (IV) tedizolid phosphate, or a single dose oral suspension of tedizolid phosphate, when administered to pediatric participants, full-term neonates, and preterm neonates.
Interventions
- DRUG IV Tedizolid Phosphate
- DRUG Oral Suspension Tedizolid Phosphate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 47 participants |
| Start Date | 2019-02-06 |
| Est. Completion | 2023-04-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03217565
The ClinicalTrials.gov registry entry for NCT03217565 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 47 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Merck Sharp & Dohme, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which IV Tedizolid Phosphate is the first listed.
NCT03217565 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03217565 about?
NCT03217565 is a clinical study titled "A Pharmacokinetic Study of Tedizolid Phosphate in Pediatric Participants With Gram-Positive Infections (MK-1986-014)". The primary objectives of this study are to describe the single-dose, and multiple dose pharmacokinetics (PK) of intravenous (IV) tedizolid phosphate, or a single dose oral suspension of tedizolid phosphate, when administered to pediatric participants, full-term neonates, and preterm neonates.
What is the current status of trial NCT03217565?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 47 participants. The study started on 2019-02-06. Estimated completion is 2023-04-06.
What interventions are being tested in trial NCT03217565?
The interventions under investigation include: IV Tedizolid Phosphate (DRUG), Oral Suspension Tedizolid Phosphate (DRUG).
Who is sponsoring clinical trial NCT03217565?
This trial is sponsored by Merck Sharp & Dohme, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.